Table 1.
The description of IC molecules、targeted monoclonal antibody drugs and indications.
| IC | Expressing cells | Targeted monoclonal antibody | Indications |
|---|---|---|---|
| PD-1 | Activated T cell, B cell, NK cell, myeloid cells | nivolumab, pembrolizumab, cemiplimab, sintilimab, camrelizumab, toripalimab, tislelizumab, zimberelimab, prolgolimab, dostarlimab | Melanoma, NSCLC, RCC, HCC, Hodgkin's lymphoma, primary mediastinal large B cell lymphoma, SCC of the head and neck, urothelial carcinoma, gastric cancer, solid tumors with high MSI, or MRD, Cutaneous squamous cell carcinoma |
| PD-L1 | various malignancies, dendritic cells | atezolizumab durvalumab avelumab |
NSCLC, urothelial carcinoma, bladder cancer, Merkel cell carcinoma |
| CTLA-4 | Activated T cell and B cells, Treg, NK cells | Ipilimumab | malignant melanoma, NSCLC, mesothelioma, prostate cancer, breast cancer, urothelial cancer |
| Tremelimumab | |||
| Tim-3 | T cell, NK cell and DC | Sabatomimab | Advanced Malignancies |
| cobolimab | |||
| LAG-3 | Activated T cell and NK cell, B cell, Treg and pDC | relatlimab | unresectable or metastatic melanoma |
| fianlimab | |||
| TIGIT | T cell and NK cell | tiragolumab | Melanoma, liver cancer, cervical cancer, prostate cancer, ESCC, breast cancer, NSCLC, NHL/DLBCL/B-cell malignancies |
| domvanalimab | |||
| ociperlimab | |||
| vibostolimab | |||
| VISTA | T cells and CD11b+ antigen-presenting cells, myeloid cells |
JNJ-61,610,588 | NSCLC, small-cell lung cancer, head and neck, pancreatic, colorectal, cervical cancer |
| Siglec-15 | tumor-associated macrophages and dendritic cells, human cancer cells cells | NC318 | advanced solid tumors |
| CD112R | T cell and NK cell | COM701 | Breast cancer, Melanoma, pancreatic cancer |
| GSK4381562 | |||
| KIR | NK cells, CD8+ T cells | lirilumab | MM, AML, relapsed/refractory lymphomas |
| NKG2A | NK cells, CD8+ T cells | monalizumab | oral squamous cell carcinoma, gynecological malignancies, relapsed hematological malignancies |
| Siglec-7/9 | T cell, NK cell and monocytes | none | NSCLC, ovarian, colorectal cancers, melanoma |
| HLA-G | various malignancies | none | Breast cancer |
| ILT2/4,KIR2DL4 | ILT2/4(T cell, NK cell, DC), KIR2DL4(NK cell) | MK-4830 (anti-ILT2) | solid malignancies and hematological malignancies |
| SIRPα | macrophages | KWAR23 | Burkitt's lymphoma, Melanoma |
| 1H9 | |||
| CD47 | many tumor cells | letaplimab | Melanoma, AML stem cells, Breast cancer |
| magrolimab | |||
| SFRs | Macrophages, NK cell | elotuzumab | MM |
| Clever-1 | Endothelial cells and TAMs | Clevegen | cutaneous and uveal melanoma, hepatobiliary, pancreatic, ovarian, oestrogen-receptor-positive breast, colorectal, gastric, gallbladder cancer and cholangiocarcinoma |
| Siglec-10 | Macrophages, B cells, activated T cells and monocytes | ONC-781(anti-CD24) | Advanced Solid Tumors, Unresectable or metastatic melanoma, Resected HCC |
HCC, hepatocellular carcinoma; MRD, minimal residual disease; MSI, microsatellite instability; NSCLC, nonsmall-cell lung carcinoma; RCC, renal cell carcinoma; SCC, squamous cell carcinoma. MM, multiple myeloma; AML, acute myeloid leukemia; ESCC, esophageal squamous cell carcinoma.